NDAOPHTHALMICSUSPENSION/DROPS
Approved
Jun 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
METIMYD is a fixed-dose ophthalmic suspension combining prednisolone acetate (corticosteroid) and sulfacetamide sodium (sulfonamide antibiotic) for topical ocular use. It treats bacterial conjunctivitis and other steroid-responsive inflammatory ocular conditions where infection risk is present. The corticosteroid reduces inflammation while the antibiotic provides antimicrobial coverage.
LOE Approaching
This legacy product faces imminent loss-of-exclusivity; brand teams are typically downsized or consolidated into smaller generic defense groups.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on METIMYD offers limited career growth opportunity given its LOE-approaching status and minimal linked job openings. Roles are primarily defensive—focused on pricing, market access, and generic competition management rather than growth launches or clinical expansion.
Brand ManagerProduct Manager
Worked on METIMYD at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.